글루카곤양펩티드-1의 췌장 외 효과

키워드

참고문헌 (61)

1. Eissele R, "Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat", Scand J Gastroenterol, 25, pp.449~454 (1990)
2. Imeryüz N, "Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms", Am J Physiol, 273(4 Pt 1), pp.G920~G927 (1997)
3. Nauck MA, "Is glucagon-like peptide 1 an incretin hormone?", Diabetologia, 42, pp.373~379 (1999)
4. Poudyal H, "Mechanisms for the cardiovascular effects of glucagon-like peptide-1", Acta Physiol (Oxf) (2015)
5. Gros R, "Cardiac function in mice lacking the glucagon-like peptide-1 receptor", Endocrinology, 144, pp.2242~2252 (2003)
6. Ban K, "Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways", Circulation, 117, pp.2340~2350 (2008)
7. Advani A, "Cardiovascular effects of incretins in diabetes", Can J Diabetes, 37, pp.309~314 (2013)
8. Nikolaidis LA, "Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion", Circulation, 109, pp.962~965 (2004)
9. Sokos GG, "Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure", J Card Fail, 12, pp.694~699 (2006)
10. Avogaro A, "Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy", Curr Diab Rep, 14, pp.483~ (2014)
11. Ban K, "Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor", Endocrinology, 151, pp.1520~1531 (2010)
12. Nagayama K, "Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1", 2 and JNK signaling pathways, 2015, pp.10, e0137960~
13. Zhan JK, "Exenatide can inhibit calcification of human VSMCs through the NF-kappaB", RANKL signaling pathway, 2014, pp.13, 153~
14. Richter G, "GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery", Am J Physiol, 265(4 Pt 1), pp.L374~L381 (1993)
15. Benito E, "Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3',5'-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes", Endocrinology, 139, pp.2363~2368 (1998)
16. Turton DD, "A role for glucagon-like peptide-1 in the central regulation of feeding", Nature, 379, pp.69~72 (1996)
17. Navarro M, "Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake", J Neurochem, 67, pp.1982~1991 (1996)
18. Scrocchi LA, "Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -", - mice, 1998, pp.139, 3127~3132
19. Flint A, "Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans", J Clin Invest, 101, pp.515~520 (1998)
20. Toft-Nielsen MB, "Continuous subcutaneous infusion of glucagon-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients", Diabetes Care, 22, pp.1137~1143 (1998)
21. McClean PL, "Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP", PS1 mice, a model of Alzheimer’s disease, 2014, pp.76(Pt A), 57~67
22. McClean PL, "The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease", J Neurosci, 31, pp.6587~6594 (2011)
23. "Identifying potential effects of liraglutide on degenerative changes" (2013)[URL]
24. "Evaluating liraglutide in Alzheimer’s disease (ELAD)" (2013)[URL]
25. "A pilot clinical trial of exendin-4 in Alzheimer’s Disease" (2015)[URL]
26. Candeias EM, "Gut-brain connection: the neuroprotective effects of the anti-diabetic drug liraglutide", World J Diabetes, 6, pp.807~827 (2015)
27. Körner M, "GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting", J Nucl Med, 48, pp.736~743 (2007)
28. Moreno C, "Renal effects of glucagon-like peptide in rats", Eur J Pharmacol, 434, pp.163~167 (2002)
29. Skov J, "Effects of GLP-1 in the kidney", Rev Endocr Metab Disord, 15, pp.197~207 (2014)
30. Crajoinas RO, "Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1", Am J Physiol Ren Physiol, 301, pp.F355~F363 (2011)
31. Moreno C, "Renal effects of glucagon-like peptide in rats", Eur J Pharmacol, 434, pp.163~167 (2002)
32. Skov J, "Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men", J Clin Endocrinol Metab, 98, pp.E664~E671 (2013)
33. Skov J, "Glucagonlike peptide-1: effect on pro-atrial natriuretic peptide in healthy males", Endocr Connect, 3, pp.11~16 (2014)
34. Mima A, "Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes", Diabetes, 61, pp.2967~2979 (2012)
35. Park CW, "Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db", db mice, 2007, pp.18, 1227~1238
36. Zheng T, "Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of osteoporosis in postmenopausal women with normal glucose tolerance", J Clin Endocrinol Metab, 100 (2015)
37. Pereira M, "Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice", Bone, 81, pp.459~467 (2015)
38. Iepsen EW, "GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women", J Clin Endocrinol Metab, 100, pp.2909~2917 (2015)
39. Driessen JH, "Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis", Calcif Tissue Int, 97, pp.104~112 (2015)
40. Bullock BP, "Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor", Endocrinology, 137, pp.2968~2978 (1996)
41. Yamato E, "Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1)", Horm Metab Res, 29, pp.56~59 (1997)
42. Villanueva-Peñacarrillo ML, "Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models", Endocrine, 15, pp.241~248 (2001)
43. Gutniak M, "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus", N Engl J Med, 326, pp.1316~1322 (1992)
44. Hansen BF, "Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport", Acta Diabetol, 35, pp.101~103 (1998)
45. Prigeon RL, "Suppression of glucose production by GLP-1 independent of islet hormones:a novel extrapancreatic effect", Am J Physiol Endocrinol Metab, 285, pp.E701~E707 (2003)
46. Murayama Y, "Glucagon-like peptide-1(7-37) does not stimulate either hepatic glycogenolysis or ketogenesis", Endocrinol Jpn, 37, pp.293~297 (1990)
47. Redondo A, "Cell signalling of the GLP-1 action in rat liver", Mol Cell Endocrinol, 204, pp.43~50 (2003)
48. Wu H, "The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats:tracer studies in the basal state and during hyperinsulinemiceuglycemic clamp", J Diabetes Res, 2014, pp.524517~ (2014)
49. Valverde I, "Pancreatic and extrapancreatic effects of GLP-1", Diabetes Metab, 28(6 Pt 2), pp.3S85~3S112 (2002)
50. Gupta NA, "Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway", Hepatology, 51, pp.1584~1592 (2010)
51. Svegliati-Baroni G, "Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis", Liver Int, 31, pp.1285~1297 (2011)
52. 이진미, "GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease", Diabetes and Metabolism Journal, 36(4), pp.262~267 (2012), 대한당뇨병학회[DOI]
53. Ding X, "Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob", ob mice, 2006, pp.43, 173~181
54. Miyazaki M, "Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism", Mol Med Rep, 5, pp.729~733 (2012)
55. Wu H, "Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats", Endocr Res (2015)
56. Ji W, "Liraglutide exerts antidiabetic effect via PTP1B and PI3K", Akt2 signaling pathway in skeletal muscle of KKAy mice, 2014, pp.2014, 312452~
57. Bullock BP, "Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor", Endocrinology, 137, pp.2968~2978 (1996)
58. Montrose-Rafizadeh C, "Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes", J Cell Physiol, 172, pp.275~283 (1997)
59. Gao H, "GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1adipocytes", Endocrine, 32, pp.90~95 (2007)
60. Tomas E, "GLP-1(32-36)amide pentapeptide increases basal energy expenditure and inhibits weight gain in obese mice", Diabetes, 64, pp.2409~2419 (2015)
61. Meier JJ, "Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans", Diabetologia, 49, pp.452~458 (2006)

관련 논문AI추천